Source:http://linkedlifedata.com/resource/pubmed/id/19808951
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-2-19
|
| pubmed:abstractText |
Topotecan pharmacokinetics at higher infusion rates (4 mg/m2 over 30 minutes) have not been studied. The authors report a pharmacokinetics and safety study of this dose in advanced cancer patients. Sixteen patients were given a 4-mg/m2 topotecan infusion intravenously (IV) over 30 minutes weekly for 3 weeks, repeated every 28 days. Pharmacokinetics were determined after the first dose. Plasma concentrations of total topotecan were measured to derive CL, V(ss), C(max), t(max), t(1/2), AUC(0-t), and AUC(0-infinity). Plasma total topotecan concentrations decreased biexponentially, with a mean CL value of 20.6 L/h, V(ss) value of 101 L, and t(1/2) value of 5.0 h. Nine significant adverse events (all hematologic) were topotecan related. Grade 3 or less adverse events included anemia, thrombocytopenia, leukopenia, and fatigue. Pharmacokinetics of the 4-mg/m2 infusion of topotecan over 30 minutes are comparable to findings from studies of lower and higher doses. Toxicities are similar to previous reports.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1552-4604
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
50
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
268-75
|
| pubmed:meshHeading |
pubmed-meshheading:19808951-Adult,
pubmed-meshheading:19808951-Aged,
pubmed-meshheading:19808951-Aged, 80 and over,
pubmed-meshheading:19808951-Anemia,
pubmed-meshheading:19808951-Antineoplastic Agents,
pubmed-meshheading:19808951-Biological Availability,
pubmed-meshheading:19808951-Chromatography, High Pressure Liquid,
pubmed-meshheading:19808951-Dose-Response Relationship, Drug,
pubmed-meshheading:19808951-Drug Administration Schedule,
pubmed-meshheading:19808951-Drug Tolerance,
pubmed-meshheading:19808951-Fatigue,
pubmed-meshheading:19808951-Female,
pubmed-meshheading:19808951-Humans,
pubmed-meshheading:19808951-Infusions, Intravenous,
pubmed-meshheading:19808951-Leukopenia,
pubmed-meshheading:19808951-Male,
pubmed-meshheading:19808951-Metabolic Clearance Rate,
pubmed-meshheading:19808951-Middle Aged,
pubmed-meshheading:19808951-Neoplasms,
pubmed-meshheading:19808951-Thrombocytopenia,
pubmed-meshheading:19808951-Topotecan
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
|
| pubmed:affiliation |
Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona 85259, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|